Merck & Co (MRK)
101.40
-0.43 (-0.42%)
NYSE · Last Trade: Dec 2nd, 3:49 PM EST
Wall Street has recently concluded a tumultuous yet ultimately resilient period, with the Dow Jones Industrial Average, S&P 500, and Nasdaq Composite all managing to edge higher in late November and early December 2025. This cautious comeback signals a complex market sentiment, where investors are meticulously weighing the promise
Via MarketMinute · December 2, 2025
There's still time to get in on these rising stars.
Via The Motley Fool · December 2, 2025
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer.
However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.
Via StockStory · December 1, 2025
Big Pharma Layoff Wave Extends Into Next Year: UNH, Merck, BMS, Novartis File New WARN Noticesstocktwits.com
Via Stocktwits · November 20, 2025
Merck Says Its Two-Drug Regimen For HIV Treatment Proven Non-Inferior To Gilead’s Biktarvy In Studystocktwits.com
Via Stocktwits · November 19, 2025
As December 1, 2025, dawns, global financial markets are grappling with a significant uptick in Treasury yields, a movement primarily catalyzed by a substantial sell-off in Japanese government debt and evolving expectations surrounding central bank policies. This surge has immediately cast a shadow of caution and a 'risk-off' sentiment across
Via MarketMinute · December 1, 2025
New York, NY – December 1, 2025 – U.S. Treasury yields have experienced a significant climb today, marking a pivotal moment for financial markets. This ascent, driven by a complex interplay of global monetary policy shifts, persistent inflation concerns, and the ever-growing specter of increased government borrowing, has sent immediate ripple
Via MarketMinute · December 1, 2025
If you are thinking in decades and not days, this trio of dividend stocks could be the perfect starting point for your fledgling portfolio.
Via The Motley Fool · November 30, 2025
There are plenty of potential winners outside the world of AI.
Via The Motley Fool · November 30, 2025
The struggling pharmaceutical giant is showing signs of life.
Via The Motley Fool · November 29, 2025
The Dow Jones Industrial Average (DJIA) has staged a remarkable comeback, successfully erasing its November 2025 losses by the month's final trading day, Friday, November 28, 2025. This significant recovery not only marked a powerful late-month surge but also extended the index's impressive streak of monthly gains to seven, injecting
Via MarketMinute · November 28, 2025
Discover Merck (MRK), a top dividend stock with a 3.58% yield, strong growth history, and excellent profitability for reliable income.
Via Chartmill · November 28, 2025
The Dow Jones Industrial Average has been on a roller-coaster ride in November 2025, experiencing significant volatility and sending mixed signals across various sectors. While the index achieved a fresh all-time high earlier in the month, it has since grappled with an "indiscriminating sell-off" fueled by concerns over an "AI
Via MarketMinute · November 25, 2025
Check out the companies making headlines yesterday:
Via StockStory · November 25, 2025
Shares of global pharmaceutical company Merck (NYSE:MRK)
jumped 4.1% in the afternoon session after Wells Fargo upgraded the stock to "Overweight" from "Equal-Weight," citing confidence in the company's future.
Via StockStory · November 24, 2025
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Merck (NYSE:MRK) and the best and worst performers in the branded pharmaceuticals industry.
Via StockStory · November 23, 2025
A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a further adjustment” in the near term, sparking a significant market rally. Following his remarks, the probability of the central bank cutting rates at its December meeting jumped from 39% to over 73%, according to the CME FedWatch tool. This positive sentiment provided relief to markets amid concerns over high valuations, particularly in AI-related stocks.
Via StockStory · November 21, 2025
The investment bank's analysts simply recognize how much has changed in just the past few years, and what that means for the near future.
Via The Motley Fool · November 21, 2025
The pharmaceutical giant's post-Keytruda plans continue to take shape.
Via The Motley Fool · November 20, 2025
Shares in the biotech company have surged on news of a big pharma takeover.
Via The Motley Fool · November 20, 2025
Via MarketBeat · November 19, 2025
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand.
The result? Over the past six months, the industry’s 7.4% return has trailed the S&P 500 by 3.6 percentage points.
Via StockStory · November 19, 2025
Merck's HIV pill met key efficacy and safety goals in Phase 3 trials, matching Biktarvy as the FDA reviews its application with a 2026 decision date.
Via Benzinga · November 19, 2025
Via MarketBeat · November 19, 2025
Via MarketBeat · November 19, 2025
